## Apogee Therapeutics Raises $345 Million in Public Offering, Strengthens Position in Immunology Market

Clinical-stage biotech firm Apogee Therapeutics has successfully closed its public offering, bringing in approximately $345 million in gross proceeds to fuel its pipeline of novel biologic therapies. The company priced its offering at $41.00 per share, with underwriters exercising their full option to purchase additional shares, demonstrating strong institutional confidence in Apogee's clinical programs.

The capital raise consisted of 8,048,782 shares of common stock, complemented by pre-funded warrants for up to 365,853 additional shares at $40.99999 per warrant, with a minimal exercise price of $0.00001. This dual-instrument structure allowed the company to attract a broad investor base while maintaining flexibility in its equity financing.

**Strategic Positioning in High-Demand Therapeutic Areas**

Apogee Therapeutics specializes in developing optimized biologics targeting the largest inflammatory and immunology (I&I) markets. The company's pipeline addresses significant unmet needs in conditions including Atopic Dermatitis (AD), asthma, Eosinophilic Esophagitis (EoE), and Chronic Obstructive Pulmonary Disease (COPD). By combining well-established biological targets with advanced antibody engineering, Apogee aims to create best-in-class therapeutics that overcome limitations of existing standard-of-care treatments.

The company's lead candidate, APG777, is currently in clinical development for Atopic Dermatitis treatment—a market characterized by significant patient unmet needs and substantial commercial potential. With four validated therapeutic targets in its portfolio, Apogee is pursuing a strategy that combines monotherapy development with potential combination approaches to maximize efficacy across its I&I franchise.

**Capital Deployment for Clinical Advancement**

The $345 million raise provides substantial runway for advancing Apogee's clinical programs through key development milestones. Leading investment banks including Jefferies, BofA Securities, Guggenheim Securities, and TD Cowen served as joint book-running managers, with BTIG participating as passive bookrunner—reflecting the institutional caliber of the offering.

The offering was conducted through an effective shelf registration statement filed with the SEC, utilizing a comprehensive prospectus to provide full transparency to investors regarding Apogee's clinical pipeline, market opportunity, and risk factors associated with early-stage biopharmaceutical development.